

## ACCELERATED DISTRIBUTION DEMONSTRATION SYSTEM

REGULATORY INFORMATION DISTRIBUTION SYSTEM (RIDS)

ACCESSION NBR: 9209300213 DOC. DATE: 92/09/22 NOTARIZED: NO DOCKET #  
 FACIL: 50-250 Turkey Point Plant, Unit 3, Florida Power and Light C 05000250  
 50-251 Turkey Point Plant, Unit 4, Florida Power and Light C 05000251  
 50-335 St. Lucie Plant, Unit 1, Florida Power & Light Co. 05000335  
 50-389 St. Lucie Plant, Unit 2, Florida Power & Light Co. 05000389

AUTH. NAME AUTHOR AFFILIATION  
 BOHLKE, W.H. Florida Power & Light Co.  
 RECIP. NAME RECIPIENT AFFILIATION  
 Document Control Branch (Document Control Desk)

SUBJECT: Forwards rept of unsatisfactory performance testing incident  
 re blind performance test specimens from CompuChem  
 Laboratories, Inc. All data reviewers instructed to compare  
 initial & repeat screening results.

DISTRIBUTION CODE: A022D COPIES RECEIVED: LTR 1 ENCL 1 SIZE: 3  
 TITLE: Fitness for Duty Program: Blind Performance Test/Other

NOTES: NRR RAGHAVAN, L 05000250  
 NRR RAGHAVAN, L 05000251

	RECIPIENT		COPIES			RECIPIENT		COPIES	
	ID CODE/NAME		LTTR	ENCL		ID CODE/NAME		LTTR	ENCL
	PD2-2 LA		1	1		PD2-2 PD		1	1
	AULUCK, R		1	1		NORRIS, J		1	1
INTERNAL:	ACRS		1	1		NRR/DRIS/RSGB		1	1
	NUDOCS-ABSTRACT		1	1		REG FILE 01		1	1
	RGN2 . 02		1	1					
EXTERNAL:	NRC PDR		1	1		NSIC		1	1
NOTES:			1	1					

NOTE TO ALL "RIDS" RECIPIENTS:

PLEASE HELP US TO REDUCE WASTE! CONTACT THE DOCUMENT CONTROL DESK,  
 ROOM P1-37 (EXT. 20079) TO ELIMINATE YOUR NAME FROM DISTRIBUTION  
 LISTS FOR DOCUMENTS YOU DON'T NEED!

TOTAL NUMBER OF COPIES REQUIRED: LTTR 12 ENCL 12



FPL

P.O. Box 14000, Juno Beach, FL 33408-0420

SEP 22 1992

L-92-272  
10 CFR 26

U. S. Nuclear Regulatory Commission  
Attn: Document Control Desk  
Washington, D. C. 20555

Gentlemen:

Re: Turkey Point Units 3 and 4  
Docket Nos. 50-250 and 50-251  
St. Lucie Units 1 and 2  
Docket Nos. 50-335 and 50-389  
10 CFR 26 Unsatisfactory Performance  
Testing Incident Report

Pursuant to 10 CFR 26, Appendix A, Section 2.8(e)(4), Florida Power and Light Company (FPL) is submitting to the NRC the enclosed report of an unsatisfactory performance testing incident. FPL submitted blind performance test specimens to FPL's contract Department of Health and Human Services (DHHS) certified laboratory, CompuChem Laboratories, Inc. The enclosed report details the investigative analysis of the unsatisfactory blind specimen result, the identification of the cause, and the corrective actions taken by the laboratory to prevent recurrence.

Please contact us if additional information is required.

Very truly yours,

W. H. Bohlke  
Vice President  
Nuclear Engineering and Licensing

WHB/DMB

Attachments

cc: Stewart D. Ebnetter, Regional Administrator, Region II, USNRC  
Senior Resident Inspector, USNRC, Turkey Point Plant  
Senior Resident Inspector, USNRC, St. Lucie Plant

9209300213 920922  
PDR ADDCK 05000250  
PDR

an FPL Group company

A022  
11

100-100

100-100

100-100



COMPUCHEM  
LABORATORIES, INC.

a subsidiary of Roche Biomedical Laboratories, Inc.

P.O. Box 12652 3308 Chapel Hill/Nelson Highway  
Research Triangle Park, NC 27709  
(919) 549-8263

September 4, 1992

Dr. Kendall Green  
Florida Power & Light  
700 Universe Boulevard  
Room V2222  
Juno Beach, FL 33408

Re: SSN: 494-78-2665  
RBL: 233-743-04800  
CCN: 49367550

Dear Dr. Green:

The above referenced specimen was received at CompuChem Laboratories on August 20, 1992 and given accession number 233-743-04800 and 49367550. It was analyzed by enzyme immunoassay (EMIT) and found to be negative for all drugs except phencyclidine (PCP). However this initial PCP EMIT test failed for quality control reasons so the specimen was scheduled for re-screening by EMIT. This second screen, which satisfied all quality control criteria, was negative for PCP, thus the specimen was reported as negative on August 21, 1992.

After receiving notification from you that the specimen should have been positive it was retested under CCN 48621601 and found to be positive by both EMIT and gas chromatography-mass spectrometry (GCMS) for PCP. The concentration of PCP being 95 ng/ml.

It appears from a review of the data that an administrative error was made in performing the second EMIT screen on the day of receipt and that a different specimen aliquot was analyzed. I am basing this on the fact that the creatinine concentration on the initial run was 50 mg/dl and on the repeat was 76 mg/dl. When the specimen was retested the creatinine concentration was 50 mg/dl.

Following this incident I have instructed all data reviewers to compare initial and repeat screening results to ensure consistency. If they are not consistent, the specimen has to be realiquoted for EMIT testing.



COMPUCHEM  
LABORATORIES, INC.

a subsidiary of Roche Biomedical Laboratories, Inc.

I must sincerely apologize for this unfortunate incident and  
if I can help you further please call me at 919-248-6810.

Most sincerely,

Michael A. Peat, Ph.D.  
Vice President, Toxicology

cc: W. Boone  
P. Childs  
J. McCarthy  
K. Verkerk  
A. Washington